Clinical Trials on No EGFR Activating Mutation

Total 185 results

Henan Cancer Hospital

Unknown

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Advanced NSCLC With EGFR Mutation

China
Hospital Erasto Gaertner
AstraZeneca

Completed

Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients

Lung Neoplasms | KRAS Gene Mutation | EGFR Gene Mutation

Brazil
TYK Medicines, Inc

Active, not recruiting

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

NSCLC | Brain Metastases | EGFR Activating Mutation | Leptomeningeal Metastasis

China
Pfizer

Recruiting

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

EGFR Mutation-positive Inoperable or Reccrent NSCLC

Japan
China Medical University Hospital

Not yet recruiting

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Non-small Cell Lung Cancer | EGFR Gene Mutation | EGFR-TKI Resistant Mutation
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | EGFR Activating Mutation

United States
Second Xiangya Hospital of Central South University
The First Affiliated Hospital of Nanchang University; Xiangya Hospital of Central... and other collaborators

Recruiting

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study) (PRECISE)

Lung Cancer, Non-small Cell | Circulating Tumor DNA | EGFR Gene Mutation | EGFR-TKI Resistant Mutation | Primary Resistance

China
Shirish M Gadgeel
AstraZeneca; Henry Ford Health System

Withdrawn

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

Lung Cancer | Non-small Cell Lung Cancer | PD-L1 Gene Mutation | KRAS Activating Mutation

United States
Puma Biotechnology, Inc.

Terminated

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations (SUMMIT)

Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

France, United States, Spain, Belgium, United Kingdom, Serbia, Australia, Israel, Canada, Denmark, Ireland, Italy, Korea, Republic of
Arog Pharmaceuticals, Inc.

Completed

A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

Newly Diagnosed AML With FLT3 Activating Mutations

United States
AIO-Studien-gGmbH
AstraZeneca

Terminated

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB (NeoIntercal)

NSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR Mutation

Germany
Chonnam National University Hospital

Completed

Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA (LiquidLung-A)

Lung Neoplasms | EGFR Gene Mutation

Korea, Republic of
Hacettepe University

Not yet recruiting

The Relationship Between Trunk Position Sense and Muscle Activation, Balance and Quality of Life in Amputees

Quality of Life | Amputation | Balance | Muscle Activation | Sense of Control

Turkey
ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, Italy, United Kingdom, France, China, Korea, Republic of, Canada, Japan, Netherlands
Second Affiliated Hospital of Nanchang University
Nanchang University

Unknown

Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer (OWBLM)

Non-small Cell Lung Cancer | EGFR Activating Mutation | Leptomeningeal Metastasis

China
Second Affiliated Hospital of Nanchang University
Nanchang University

Unknown

Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis (OWONBNSCLCLM)

Non-small Cell Lung Cancer | EGFR Activating Mutation | Leptomeningeal Metastasis
xCures
Cancer Commons

Available

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Melanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditions

United States
Kantonsspital Aarau

Completed

Clinical Trial Comparing Conventional and Robot-assisted(Da Vinci®)Laparoscopic Interventions for Hysterectomy

Postoperative Complications | Intraoperative Complications | Laparoscopic Technique no Switch to Open | Duration of Surgery

Switzerland
Medical University of Vienna

Recruiting

Long-term Results of Two Surgical Methods for Scleral IOL Implantation and Fixation in Eyes Without Capsular Support: Yamane- Versus 4-flanged Technique (YAMPOINT)

Lens Luxation | IOL Subluxation | IOL Opacification | Aphakia - No Lens Capsule

Austria
Jonsson Comprehensive Cancer Center
AstraZeneca

Active, not recruiting

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma

Glioblastoma | Recurrent Glioblastoma | EGFR Gene Mutation | Supratentorial Glioblastoma | EGFR Gene Amplification | TP53 wt Allele

United States
Taiho Oncology, Inc.

Terminated

TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations

Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations | Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations

United States, United Kingdom, Austria, France
Hellenic Cooperative Oncology Group

Completed

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Gene Mutation
Betta Pharmaceuticals Co., Ltd.

Unknown

Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer (CHALLENGE)

Plasma EGFR Mutation-positive Lung Cancer

China
Arog Pharmaceuticals, Inc.

Recruiting

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

United States, Germany, Spain, Italy, France, Canada
National Taiwan University Hospital

Recruiting

Applying Mobile Healthcare Education to Improve Cutaneous Self-care Capability

Cancer | Drug-Related Side Effects and Adverse Reactions | Cancer, Treatment-Related | EGFR Gene Mutation

Taiwan
Chonnam National University Hospital

Completed

Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA (LiquidLung-O)

Lung Neoplasms | EGFR Gene Mutations

Korea, Republic of
Arog Pharmaceuticals, Inc.

Completed

Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations

Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

United States
Bayer

Recruiting

A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United States
Bayer

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

Hong Kong, United States, Taiwan, Spain, Belgium, China, Japan, France, Korea, Republic of, Singapore, Poland, Israel, Italy, Netherlands, Portugal, Brazil
Fudan University

Unknown

Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer (APPEAL)

Lung Cancer, Non-small Cell | EGFR Gene Mutation | EGFR T790M

China
Collin Blakely
Puma Biotechnology, Inc.

Active, not recruiting

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Lung Cancer Metastatic | EGFR Gene Mutation

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | EGFR Activating Mutation | Stage IV Non-Small Cell Lung Cancer AJCC v7 | ALK Gene Translocation | Stage IIIB Non-Small Cell Lung Cancer AJCC v7 | ROS1 Gene Translocation

United States
Bayer

Recruiting

A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United States
Bayer

Recruiting

A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United Kingdom
Bayer

Completed

A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

Netherlands
Instituto Nacional de Cancerologia de Mexico

Unknown

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

EGFR Gene Mutation | Tyrosine Kinase Mutation | Non-Small Cell Adenocarcinoma

Mexico
AstraZeneca

Completed

Europe-Japan Diagnostic Study for EGFR Testing (ASSESS)

EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.

Italy, Spain, United Kingdom, Sweden, Japan, Netherlands, Germany, France
Bayer

Recruiting

A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United States
Memorial Sloan Kettering Cancer Center

Completed

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

Lung Cancer | Lung Cancer Metastatic | EGFR Gene Mutation

United States
Degan Lu
Wu Jieping Medical Foundation

Not yet recruiting

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

Lung Cancer | Anlotinib | TKI Resistance | EGFR Sensitive Mutation | Pianzumab
Centre Francois Baclesse
GFPC

Recruiting

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (GFPC 06-2018)

ALK Gene Rearrangement Positive | NSCLC Stage IV | NSCLC Stage IIIB | EGFR Gene Mutation | ROS1 Gene Mutation

France
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7 | EGFR Exon 19 Deletion Mutation | EGFR NP_005219.2:p.L858R

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment

NSCLC | EGFR Gene Mutation

China
Hideho Okada, MD, PhD
National Cancer Institute (NCI); California Institute for Regenerative Medicine...

Recruiting

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

Glioblastoma | Recurrent Glioblastoma | EGFR Gene Mutation | MGMT-Unmethylated Glioblastoma

United States
Peking Union Medical College

Recruiting

Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Single-center, Open-label, Phase II Trial（iFORCE）

NSCLC | Brain Metastases | Furmonertinib | EGFR-mutation

China
Betta Pharmaceuticals Co., Ltd.

Active, not recruiting

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Non-Small Cell Lung Cancer | EGFR Gene Mutation

China
Fujian Cancer Hospital

Unknown

Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation (Geber)

Lung Adenocarcinoma | EGFR Mutation

China
Shanghai Pulmonary Hospital, Shanghai, China

Unknown

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Nonsmall Cell Lung Cancer | EGFR Gene Mutation
AstraZeneca

Completed

Phase I, Study in Chinese NSCLC Patients (AURAChinaPK)

Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive

China
Intergroupe Francophone de Cancerologie Thoracique

Active, not recruiting

Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (ORBITAL)

Non Small Cell Lung Cancer Metastatic | Brain Metastases | EGFR Activating Mutation | Leptomeningeal Metastasis

France

Clinical Trials on No EGFR Activating Mutation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations